



UNIVERSITAT DE
BARCELONA

Efecto del síndrome metabólico provocado por una dieta rica en grasa en ratones APP^{swe}/PS1^{dE9}, modelo experimental de la enfermedad de Alzheimer, y posibles terapias farmacológicas

Miren Ettcheto Arriola

ADVERTIMENT. La consulta d'aquesta tesi queda condicionada a l'acceptació de les següents condicions d'ús: La difusió d'aquesta tesi per mitjà del servei TDX (www.tdx.cat) i a través del Dipòsit Digital de la UB (diposit.ub.edu) ha estat autoritzada pels titulars dels drets de propietat intel·lectual únicament per a usos privats emmarcats en activitats d'investigació i docència. No s'autoritza la seva reproducció amb finalitats de lucre ni la seva difusió i posada a disposició des d'un lloc aliè al servei TDX ni al Dipòsit Digital de la UB. No s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX o al Dipòsit Digital de la UB (framing). Aquesta reserva de drets afecta tant al resum de presentació de la tesi com als seus continguts. En la utilització o cita de parts de la tesi és obligat indicar el nom de la persona autora.

ADVERTENCIA. La consulta de esta tesis queda condicionada a la aceptación de las siguientes condiciones de uso: La difusión de esta tesis por medio del servicio TDR (www.tdx.cat) y a través del Repositorio Digital de la UB (diposit.ub.edu) ha sido autorizada por los titulares de los derechos de propiedad intelectual únicamente para usos privados enmarcados en actividades de investigación y docencia. No se autoriza su reproducción con finalidades de lucro ni su difusión y puesta a disposición desde un sitio ajeno al servicio TDR o al Repositorio Digital de la UB. No se autoriza la presentación de su contenido en una ventana o marco ajeno a TDR o al Repositorio Digital de la UB (framing). Esta reserva de derechos afecta tanto al resumen de presentación de la tesis como a sus contenidos. En la utilización o cita de partes de la tesis es obligado indicar el nombre de la persona autora.

WARNING. On having consulted this thesis you're accepting the following use conditions: Spreading this thesis by the TDX (www.tdx.cat) service and by the UB Digital Repository (diposit.ub.edu) has been authorized by the titular of the intellectual property rights only for private uses placed in investigation and teaching activities. Reproduction with lucrative aims is not authorized nor its spreading and availability from a site foreign to the TDX service or to the UB Digital Repository. Introducing its content in a window or frame foreign to the TDX service or to the UB Digital Repository is not authorized (framing). Those rights affect to the presentation summary of the thesis as well as to its contents. In the using or citation of parts of the thesis it's obliged to indicate the name of the author.

CONCLUSIONES

CONCLUSIONS

The conclusions of the present doctoral thesis are the following:

Effect of HFD in a presymptomatic stage of APP/PS1 familial AD mice model

1. The HFD favours the development of AD at 3-month-old of age through different mechanisms:
 - a) The HFD increases APP and decreases BACE1 protein levels, resulting in an increase of A β ₁₋₄₀ soluble and insoluble and β A₁₋₄₂ insoluble in cortex and, therefore, an increase of plaque deposition. Moreover, the HFD decreases insulin degrading enzyme (IDE) protein levels, which also contributes to plaque deposition.
 - b) The HFD together with A β shows a synergistic effect which favours cognitive loss.
 - c) At the molecular level, the HFD provokes the decrease of p-CREB and PGC1 α protein levels, suggesting that they could represent a potential risk factor in the onset and progression of AD. Therefore, their preservation in the brain might be a molecular target mechanism providing neuroprotection against metabolic AD.

Effect of chronic administration of DXI in APP/PS1 familial AD mice model

1. The chronic treatment of DXI provokes a reduction in the neuroinflammatory process, resulting in the decrease of NFT through c-ABL/CABLES/CDK5 pathway, reduction of A β deposition and enhancement of insulin signalling leading to a memory improvement.
2. This study demonstrates that chronic administration of DXI could exert multiples beneficial affects against AD development, as preventive treatment or as a coadjuvant drug together with others.

Effect of MEM in mixed preclinical mice model of obesity, induced by the intake of HFD, and familial AD

1. MEM ameliorates learning and memory deficits, activating insulin signalling pathway, decreasing PTP1B protein levels, inhibiting glial activation, as well as, enhancing synaptic proteins and decreasing A β deposition in obese APP/PS1 mice.
2. MEM improves peripheral parameters such as HFD-intake induced hyperglycaemia, insulin resistance and body weight gain in APP/PS1 but not in WT mice, suggesting that MEM could interact with A β in the brain, contributing synergically with HFD causing insulin resistance process in APP/PS1.
3. MEM ameliorates insulin signalling in the liver, regulating IRS2 and its downstream targets, suggesting that this drug could be a potential treatment for T2DM and additional liver pathologies.